Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
5.05
+0.05 (1.00%)
Jan 21, 2025, 4:00 PM EST - Market closed
Codexis Revenue
Codexis had revenue of $12.83M in the quarter ending September 30, 2024, with 38.33% growth. This brings the company's revenue in the last twelve months to $64.45M, down -12.86% year-over-year. In the year 2023, Codexis had annual revenue of $70.14M, down -49.39%.
Revenue (ttm)
$64.45M
Revenue Growth
-12.86%
P/S Ratio
5.52
Revenue / Employee
$370,379
Employees
174
Market Cap
410.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 70.14M | -68.45M | -49.39% |
Dec 31, 2022 | 138.59M | 33.84M | 32.30% |
Dec 31, 2021 | 104.75M | 35.70M | 51.69% |
Dec 31, 2020 | 69.06M | 598.00K | 0.87% |
Dec 31, 2019 | 68.46M | 7.86M | 12.98% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
CDXS News
- 5 days ago - Codexis Appoints Christos Richards to Board of Directors - GlobeNewsWire
- 11 days ago - Codexis Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics - GlobeNewsWire
- 2 months ago - Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors - GlobeNewsWire
- 2 months ago - Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics - GlobeNewsWire
- 2 months ago - Codexis to Participate in Upcoming Healthcare Conferences - GlobeNewsWire
- 2 months ago - Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript - Seeking Alpha